INmune Bio Inc INMB

US Biotechnology

$1.14 ▲ +0.89% (+$0.01)

Open $1.13

Prev Close $1.13

Day Range $1.08 – $1.15

52W Range $1.06 – $2.60

Market Cap $34.98M

Beta 1.04

EPS (TTM) $-0.69

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-02-04
Shares Out.	30,960,000
Website	inmunebio.com/ ↗
Phone	18589643720
Employees	21
Revenue	$0
Gross Profit	$0
Net Income	-$1.3M
Free Cash Flow	-$15.7M
Total Assets	$26.8M
Total Liabilities	$6.5M
Equity	$20.4M

About INmune Bio Inc

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

INmune Bio Inc is a publicly traded company under the ticker symbol INMB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.